Literature DB >> 12573756

Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).

Cesare Cozzarini1, Claudio Fiorino, Giovanni Luca Ceresoli, Giovanni Mauro Cattaneo, Angelo Bolognesi, Riccardo Calandrino, Eugenio Villa.   

Abstract

PURPOSE: Investigating the correlation between dosimetric/clinical parameters and late rectal bleeding in patients treated with adjuvant or salvage radiotherapy after radical prostatectomy. METHODS AND MATERIALS: Data of 154 consecutive patients, including three-dimensional treatment planning and dose-volume histograms (DVHs) of the rectum (including filling), were retrospectively analyzed. Twenty-six of 154 patients presenting a (full) rectal volume >100 cc were excluded from the analysis. All patients considered for the analysis (n = 128) were treated at a nominal dose equal to 66.6-70.2 Gy (ICRU dose 68-72.5 Gy; median 70 Gy) with conformal (n = 76) or conventional (n = 52) four-field technique (1.8 Gy/fr). Clinical parameters such as diabetes mellitus, acute rectal bleeding, hypertension, age, and hormonal therapy were considered. Late rectal bleeding was scored using a modified Radiation Therapy Oncology Group scale, and patients experiencing >or=Grade 2 were considered bleeders. Median follow-up was 36 months (range 12-72). Mean and median rectal dose were considered, together with rectal volume and the % fraction of rectum receiving more than 50, 55, 60, and 65 Gy (V50, V55, V60, V65, respectively). Median and quartile values of all parameters were taken as cutoff for statistical analysis. Univariate (log-rank) and multivariate (Cox hazard model) analyses were performed.
RESULTS: Fourteen of 128 patients experienced >or=Grade 2 late bleeding (3-year actuarial incidence 10.5%). A significant correlation between a number of cutoff values and late rectal bleeding was found. In particular, a mean dose >or=54 Gy, V50 >or=63%, V55 >or=57%, and V60 >or=50% was highly predictive of late bleeding (p <or= 0.01). A rectal volume <60 cc and type of treatment (conventional vs. conformal) were also significantly predictive of late bleeding (p = 0.05). Concerning clinical variables, acute bleeding (p < 0.001) was significantly related to late bleeding, and a trend was found for hypertension (p = 0.11). After patients were grouped into those with V50 >or=63% and those with V50 <63% (DVH grouping), data were fitted with a Cox regression hazard model using DVH grouping, rectal volume, and the main clinical parameters as independent variables. Results of the analysis showed that DVH grouping (relative risk 3.3; p = 0.04) and acute bleeding (relative risk 7.1; p = 0.001) are independently predictive of late bleeding.
CONCLUSIONS: DVHs of the rectum are significantly correlated with late bleeding for patients irradiated at 66.6-70.2 Gy after radical prostatectomy.

Entities:  

Mesh:

Year:  2003        PMID: 12573756     DOI: 10.1016/s0360-3016(02)04117-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Dose-volume Histogram-based Predictors for Hematuria and Rectal Hemorrhage in Patients Receiving Radiotherapy After Radical Prostatectomy.

Authors:  Katsuyuki Shirai; Masato Suzuki; Keiko Akahane; Yuta Takahashi; Masahiro Kawahara; Erika Yamada; Masaru Wakatsuki; Kazunari Ogawa; Satrou Takahashi; Kyosuke Minato; Kohei Hamamoto; Kimitoshi Saito; Masashi Oshima; Tsuzumi Konishi; Yuhki Nakamura; Satoshi Washino; Tomoaki Miyagawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.

Authors:  Pilar M Samper; M Concepción López Carrizosa; Ana Pérez Casas; Carmen Vallejo; M Carmen Rubio Rodríguez; Consuelo Pérez Vara; Miguel Melchor Iñiguez
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

3.  Interfractional fluctuation of rectal dose in high dose rate brachytherapy for prostate cancer.

Authors:  Hime Ishikawa; Morio Sato; Shintaro Shirai; Kazushi Kishi; Yoshitaka Naya; Hisaki Tokunaga
Journal:  Radiat Med       Date:  2006-11-24

4. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

5.  Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?

Authors:  Mirko Nitsche; Werner Brannath; Matthias Brückner; Dirk Wagner; Alexander Kaltenborn; Nils Temme; Robert M Hermann
Journal:  Br J Radiol       Date:  2016-12-12       Impact factor: 3.039

6.  A dosimetric analysis of volumetric-modulated arc radiotherapy with jaw width restriction vs 7 field intensity-modulated radiotherapy for definitive treatment of cervical cancer.

Authors:  B Huang; Z Fang; Y Huang; P Lin; Z Chen
Journal:  Br J Radiol       Date:  2014-05-16       Impact factor: 3.039

7.  The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Authors:  Antonio José Conde-Moreno; Carlos Ferrer-Albiach; Mercedes Zabaleta-Meri; Xavi J Juan-Senabre; Agustín Santos-Serra
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 8.  Radiation dose-volume effects in radiation-induced rectal injury.

Authors:  Jeff M Michalski; Hiram Gay; Andrew Jackson; Susan L Tucker; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

9.  Modeling plan-related clinical complications using machine learning tools in a multiplan IMRT framework.

Authors:  Hao H Zhang; Warren D D'Souza; Leyuan Shi; Robert R Meyer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

10.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Authors:  Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.